# A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

> **NCT01130519** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 83 (actual)

## Conditions studied

- HLRCC
- Sporadic Papillary Renal Cell Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01130519
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-06
- **Primary completion:** 2022-04-12
- **Final completion:** 2022-06-08
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130519, "A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01130519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*